Telestream Integrates with Verimatrix Streamkeeper Multi-DRM, Emphasizes Video Quality Monitoring and Analytics
14.9.2022 18:02:00 EEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, and Telestream, a global leader in video quality monitoring, test and measurement solutions, today announced that Surveyor ABR Active, Telestream iQ's ABR streaming QoE and QoS monitoring technology, is integrated within Verimatrix StreamkeeperSM Multi-DRM, available in the Verimatrix Secure Delivery Platform.
Through the integration, Telestream further builds on its innovative offerings for the digital video industry which include workflow automation, media processing, and quality monitoring solutions for the production and distribution of video. Telestream’s integration with Streamkeeper Multi-DRM allows users to capitalize on Verimatrix’ s cost-effective cloud-based solution while maintaining full visibility into video and audio content quality. Together, Verimatrix and Telestream accelerate time to market while maintaining service visibility for operators.
Verimatrix Streamkeeper Multi-DRM delivers studio endorsed best practices for content protection, with meticulous focus on ensuring superior video viewer experiences. As a suite of adaptive cybersecurity technologies that include and go beyond DRM, Streamkeeper allows video service providers to manage revenue risk in a world of continuously changing threats from video piracy and cybercriminals.
Telestream’s video quality monitoring solutions are trusted worldwide to provide video service assurance and operational visibility for valuable live and on-demand video services. As digital workflows move to the cloud, Telestream’s pedigree monitoring solutions, coupled with Verimatrix, means those planning to migrate their video workflows to the cloud will have equal or better operational visibility than ever before.
Telestream iQ provides full video and audio quality analysis both at the transcoding location and post CDN for live and on-demand services, allowing operators full visibility into content quality issues – even with full security encryption in place. Telestream iQ’s solutions ensure that audio and video quality errors such as compression errors, pixelization, black screen, still frame, and audio loudness are caught early, allowing rapid time-to-resolution and the ongoing protection of revenue and reputation.
“A longstanding alliance partner of Verimatrix, Telestream is proud to be one of its first partners to integrate with Streamkeeper Multi-DRM,” said Joel Daly, vice president of product management at Telestream. “Together we provide a solution that builds security, service assurance and operational visibility into cloud video workflows, de-risking the migration to cloud for global content and video service providers.”
“We’re extremely pleased to work with such highly-recognized industry visionaries such as Telestream as we continue to widen the number the number of integrated solutions available within Verimatrix Streamkeeper Multi-DRM,” said Sebastian Braun, senior director of product management at Verimatrix. “We’re pleased to continue our acceleration of additive value adoption through a global network of trusted partners.”
Verimatrix Streamkeeper is available in multiple tiers and includes features such as a real-time performance dashboard, on-call support integrations and alerts, individual device risk scoring and anti-piracy countermeasures.
Surveyor ABR Active provides essential insights that enable content owners and streaming service providers to manage critical issues relate to Quality of Service (QoS) and Quality of Experience (QoE) for live and on-demand services. It acts as the most critical viewer, measuring video flows for every bitrate variant and format.
For more information about Verimatrix Streamkeeper, visit: www.verimatrix.com/products/streamkeeper.
About Telestream
For nearly 25 years, Telestream® has been at the forefront of innovation in the digital video industry. The company develops products for media processing and workflow orchestration, live capture, streaming, production, video quality assurance, virtual events and video hosting, content management, and video and audio test solutions. Available on premises or in the cloud as well as in hybrid combinations, Telestream solutions make it possible to reliably get video content to any audience, regardless of how it is created, distributed or viewed. Telestream is privately held with corporate headquarters located in Nevada City, California and Westwood, Massachusetts.
For company and product information, visit www.Telestream.net.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005371/en/
Contact information
Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com
Telestream Media Contacts:
North America
Doug Hansel
doug@highrezpr.com
+1-603-537-9248
EMEA & APAC
Jeneane Ezzell
jeneane@highrezpr.com
+44 7790 411561
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom